Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

News > Madrid

Find below news from the community Madrid in Spain. Listed are news about this region as well as from organisations located there.

Total search results: 125 | Ordered by Date (descending)
1 2  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
Oryzon Genomics S.A.. (10/26/18). "Press Release: Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors [Not for US, CA, AU, JP, ZA or any other jurisdiction where unlawful]". Madrid & Cambridge, MA. 2018-10-26
Minoryx Therapeutics S.L.. (9/21/18). "Press Release: A Consortium Led by Minoryx Receives €0.8m to Explore Additional Indications for MIN-102". 2018-09-21
Nordic Nanovector ASA. (6/25/18). "Press Release: Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer". Oslo. 2018-06-25
Oryzon Genomics S.A.. (5/14/18). "Press Release: Oryzon Announces First Patients In ETHERAL – a Phase IIa Clinical Trial in Alzheimer’s Disease with ORY-2001". Madrid & Cambridge, MA. 2018-05-14
Phenomenex, Inc.. (5/2/18). "Press Release: Phenomenex Expands International Network with Direct Sales to Portugal". Torrance, CA. 2018-05-02
Bruker Corporation. (4/20/18). "Press Release: Bruker Introduces Bologna Workflow for Rapid and Cost-Effective Clinical Microbiology Diagnosis of Bloodstream Infections with Broad Species Coverage". Madrid. 2018-04-20
Curetis N.V.. (4/19/18). "Press Release: Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018". Amsterdam, San Diego, CA & Holzgerlingen. 2018-04-19
Curetis N.V.. (4/18/18). "Press Release: Curetis – Novel Products and Study Data to Be Presented at ECCMID 2018". Amsterdam, San Diego, CA & Holzgerlingen. 2018-04-18
PharmaMar S.A.. (2/14/18). "Press Release: PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates". Madrid. 2018-02-14
Genomica SAU. (1/18/18). "Press Release: Genomica Opens Its First Subsidiary in China". Madrid. 2018-01-18
PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid). 2018-01-18
Oryzon Genomics S.A.. (10/3/17). "Press Release: Significant Fact [Company Moves Registered Address from Barcelona to Madrid]". Madrid. 2017-10-03
Merck KGaA. (8/31/17). "Press Release: Driving Innovation in Cancer Care at ESMO 2017 with New Data in Hard-to-Treat Cancers [Not intended for U.K. or U.S. based media]". Darmstadt. 2017-08-31
Amcure GmbH. (8/23/17). "Press Release: Amcure Announces Formation of Inaugural Scientific Advisory Board". Eggenstein-Leopoldshafen. 2017-08-23
Oryzon Genomics S.A.. (7/20/17). "Press Release: Oryzon to Regain Rights to ORY-1001 (RG6016)". Barcelona & Cambridge, MA. 2017-07-20
Oryzon Genomics S.A.. (5/31/17). "Press Release: Oryzon Genomics to Participate in a Panel at the JMP Securities Life Sciences Conference and Present at the Jefferies 2017 Global Health Conference". Barcelona & Cambridge, MA. 2017-05-31
PharmaMar S.A.. (5/18/17). "Press Release: PharmaMar Announces New Data with Its Compounds Yondelis and Lurbinectedin during ASCO 2017". Madrid. 2017-05-18
AptaTargets. (5/17/17). "Press Release: AptaTargets Closes €2.7 Million Round of Funding for New Stroke Treatment". Madrid. 2017-05-17
PharmaMar S.A.. (5/17/17). "Press Release: PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries". Madrid. 2017-05-17
Oryzon Genomics S.A.. (5/16/17). "Press Release: Oryzon Announces Appointment of New Chief Medical Officer and Expansion of Its Medical Department". Barcelona & Cambridge, MA. 2017-05-16
PharmaMar S.A.. (5/4/17). "Press Release: Aplidin Receives Orphan Drug Status for the Treatment of Multiple Myeloma in Switzerland". Madrid. 2017-05-04
Oryzon Genomics S.A.. (3/31/17). "Press Release: Oryzon Raises €18 Million through a Private Placement with US and European Investors [Not for US, CA, AU, JP, ZA, et al.]". Barcelona. 2017-03-31
Oryzon Genomics S.A.. (2/27/17). "Press Release: Oryzon Presented New Preclinical Data of ORY-2001 Therapeutic Activity in Multiple Sclerosis at ACTRIMS-2017". Barcelona & Cambridge, MA. 2017-02-27
mAbxience S.L.. (2/13/17). "Press Release: mAbxience, European Success Accelerating Global Growth". 2017-02-13
Iproteos S.L.. (1/26/17). "Press Release: Grant of 700,000 € for the Discovery of Drugs against Atherosclerosis". 2017-01-26
PharmaMar S.A.. (12/1/16). "Press Release: PharmaMar Presents Positive Results with Its Conjugated Antibody MI130110 in CD13-expressing Tumor-cells". Madrid. 2016-12-01
PharmaMar S.A.. (11/28/16). "Press Release: PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors". Madrid. 2016-11-28
PharmaMar S.A.. (11/10/16). "Press Release: PharmaMar Shows New Clinical Data with Yondelis in Different Sarcoma Subtypes at CTOS 2016". Madrid. 2016-11-10
PharmaMar S.A.. (10/28/16). "Press Release: The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin". Madrid. 2016-10-28
PharmaMar S.A.. (10/27/16). "Press Release: PharmaMar Group Reports 9M 2016 Financial Results". Madrid. 2016-10-27
Sygnis AG. (10/27/16). "Press Release: Sygnis AG to Receive €1.9 Million Non-dilutive R&D Funding from the Spanish Government". Madrid & Heidelberg. 2016-10-27
PharmaMar S.A.. (10/24/16). "Press Release: PharmaMar Announces the Opening of a New Affiliate in Austria". Madrid. 2016-10-24
PharmaMar S.A.. (10/4/16). "Press Release: PharmaMar and Boryung Pharm Sign a Licensing Agreement for Aplidin (plitidepsin) in Korea". Madrid. 2016-10-04
Eurofins Scientific. (9/30/16). "Press Release: Eurofins Expands Its Clinical Diagnostic Footprint with the Acquisition of Megalab in Spain". 2016-09-30
Oryzon Genomics S.A.. (9/26/16). "Press Release: Oryzon Closes € 5.3 Million (6 M USD) in Additional Debt Financing". Barcelona & Cambridge, MA. 2016-09-26
PharmaMar S.A.. (9/22/16). "Press Release: PharmaMar Submits MAA to EMA for Aplidin for the Treatment of Multiple Myeloma". Madrid. 2016-09-22
Oryzon Genomics S.A.. (9/1/16). "Press Release: Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016". Barcelona & Cambridge, MA. 2016-09-01
PharmaMar S.A.. (8/2/16). "Press Release: PharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer". Madrid. 2016-08-02
Oryzon Genomics S.A.. (5/18/16). "Press Release: Oryzon to Extend Its R&D Collaboration on ORY-1001 until March 2017". Barcelona & Cambridge, MA. 2016-05-18
Oryzon Genomics S.A.. (5/12/16). "Press Release: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update". Barcelona & Cambridge, MA. 2016-05-12
Oryzon Genomics S.A.. (5/4/16). "Press Release: Oryzon Closes € 10.5 Million (12.1 M USD) Debt Financing". Barcelona & Cambridge, MA. 2016-05-04
Thermo Fisher Scientific Inc.. (12/15/15). "Press Release: Thermo Fisher Scientific Awards 2015 Attune NxT Flow Cytometry Grant to California Cancer Researcher". Albany, NY. 2015-12-15
Oryzon Genomics S.A.. (12/10/15). "Press Release: Oryzon Genomics Announces Listing on Madrid Stock Exchange". Barcelona & Cambridge, MA. 2015-12-10
Sygnis AG. (11/17/15). "Press Release: Sygnis AG Plans to Issue New Shares to Finance further Growth and Commercialization of Proprietary Product Portfolio [Not for US, CA, JP and AU] NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, 2015-11-17
PharmaMar S.A.. (11/2/15). "Press Release: PharmaMar Begins Trading on Spanish BME Stock Exchange. PharmaMar Trading Following a Merger with Zeltia". Madrid. 2015-11-02
Oryzon Genomics S.A.. (10/27/15). "Press Release: Oryzon Raises $19 Million in Private Placement to Advance Therapeutic Programs". Barcelona & Cambridge, MA. 2015-10-27
Servier. (10/5/15). "Press Release: Servier Offers Its Expertise in Industrial R&D, Chemical Synthesis and Pharmaceutical Manufacturing to Partners". 2015-10-05
Zeltia S.A.. (9/15/15). "Press Release: PharmaMar Opens New Affiliate in UK". Madrid. 2015-09-15
Zeltia S.A.. (9/1/15). "Press Release: Pharmaceutical Council Recommends Approval of Yondelis (trabectedin) in Japan". Madrid. 2015-09-01
Zeltia S.A.. (8/20/15). "Press Release: PharmaMar Announces License Agreement with Specialised Therapeutics Australia Pty for Aplidin (plitidepsin) in Oncology". Madrid. 2015-08-20
Zeltia S.A.. (7/31/15). "Press Release: PharmaMar Passes the U.S. FDA Manufacturing Inspection for Yondelis Active Ingredient". Madrid. 2015-07-31
TiGenix N.V.. (7/30/15). "Press Release: TiGenix Expands Pipeline and Enters the Cardiology Field with Clinical-stage Company Acquisition". Leuven. 2015-07-30
Zeltia S.A.. (7/28/15). "Press Release: Grupo Zeltia Reports First Half 2015 Financial Results". Madrid. 2015-07-28
Zeltia S.A.. (7/23/15). "Press Release: PharmaMar Announces License Agreement with TTY Biopharm for Aplidin (plitidepsin) in Hematological Cancers". Madrid. 2015-07-23
Zeltia S.A.. (7/22/15). "Press Release: Genomica and the Foundation for Excellence and Quality in Oncology Announce a Framework Agreement for Collaboration in Oncology". Madrid. 2015-07-22
Zeltia S.A.. (6/29/15). "Press Release: PharmaMar Initiates the Phase III Study CORAIL for the Anticancer Agent PM1183 in Patients with Platinum-resistant Ovarian Cancer". Madrid. 2015-06-29
Sygnis AG. (5/13/15). "Press Release: Sygnis AG Announces Genetrix S.L. Has Taken Over All Shares from Genetrix Life Sciences AB to Become New Majority Shareholder". Madrid & Heidelberg. 2015-05-13
Phenomenex, Inc.. (5/1/15). "Press Release: Phenomenex Acquires Micron Analitica S.A. in Spain to Expand Global Presence". Torrance, CA. 2015-05-01
3P Biopharmaceuticals S.L.. (4/23/15). "Press Release: 3P Biopharmaceuticals Produces a Cellular Drug for the First Clinical Trial of Acute Myocardial Infarction with Allogeneic Cardiac Stem Cells". 2015-04-23
Zeltia S.A.. (2/26/15). "Press Release: Zeltia's Board of Directors Will Propose to the Next Shareholders' Meeting that Pharma Mar Merge with and Absorb Its Parent Company, Zeltia. The Board of Directors Will also Request that Pharma Mar Seek an IPO in 2015-02-26
Zeltia S.A.. (2/26/15). "Press Release: Grupo Zeltia Net Attributable Profit Amounted to 13 Million Euro in 2014 (+16%). Group Total Revenues Amounted to 178 Million Euro (+8%).". Madrid. 2015-02-26
Zeltia S.A.. (2/3/15). "Press Release: U.S. FDA Grants Priority Review to Yondelis NDA for Advanced Soft-tissue Sarcoma". Madrid. 2015-02-03
Sygnis AG. (01/21/15). "Press Release: Sygnis Signs Distribution Agreement with BioNova Cientifica, for its Innovative TruePrime Single Cell WGA Kit in Spain". Madrid. 2015-01-21
Zeltia S.A.. (1/13/15). "Press Release: PharmaMar Will Start a Phase III Study of PM1183 in Combination with Doxorubicin in Relapsed SCLC". Madrid. 2015-01-13
Zeltia S.A.. (12/2/14). "Press Release: Zeltia Announces that Its Board of Directors Has Approved a Strategy to Explore Merging PharmaMar and Zeltia in Advance of a Listing Request in the US". Madrid. 2014-12-02
Zeltia S.A.. (11/25/14). "Press Release: PharmaMar Announces that Its Partner Janssen Has Submitted a New Drug Application for Yondelis to the U.S. FDA for the Treatment of Advanced Soft Tissue Sarcoma". Madrid. 2014-11-25
Cambridge Crystallographic Data Centre. (11/20/14). "Press Release: Eleven More Countries Adopt Cambridge Structural Database System National Provision. Academia in 17 Countries Enjoy Unlimited Access to Cambridge Structural Database". Cambridge & Piscat 2014-11-20
Zeltia S.A.. (11/20/14). "Press Release: PharmaMar Results for Antitumoral Compounds and Their Mechanism of Action at EORTC-NCI-AACR Emphasize an Innovative Pipeline of Targeted Ttherapies". Barcelona. 2014-11-20
Scienion AG. (10/29/14). "Press Release: Collaboration between Scienion and Genomica Results in a Novel Multiplex Based Detection Kit for the Identification and Specific Differentiation of 18 Microorganisms Causing Sexual Transmitted Infections (STIs)". 2014-10-29
Oryzon Genomics S.A.. (9/19/14). "Press Release: Oryzon Reinforces Its Board of Directors". Barcelona. 2014-09-19
Roche. (9/17/14). "Press Release: Roche to Present Latest Oncology Advances during ESMO 2014 Congress". Basel. 2014-09-17
Thermo Fisher Scientific Inc.. (9/3/14). "Press Release: Thermo Fisher Scientific Teams with National Reference Labs on New European Regulation, Allowing GC-MS/MS to Confirm Dioxins in Feed and Food". 2014-09-03
Zeltia S.A.. (7/23/14). "Press Release: PharmaMar Initiates a Phase I Study with Aplidin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma". Madrid. 2014-07-23
Zeltia S.A.. (7/17/14). "Press Release: Sylentis Receives Authorisation to Commence Phase IIb Clinical Trial with Bamosiran (SYL040012) for Treating Ocular Hypertension Associated with Glaucoma". Madrid. 2014-07-17
Roche. (4/7/14). "Press Release: Roche and Oryzon Announce Collaboration to Develop Epigenetics-based Medicines". Basel & Barcelona. 2014-04-07
Zeltia S.A.. (2/28/14). "Press Release: Zeltia Net Profit Soars 72%. Reported EBITDA of 23.8 Million Euros Increased by 16.6%". Madrid. 2014-02-28
Almirall S.A.. (2/24/14). "Press Release: Almirall’s Full-year Results 2013 – Setting the Foundations for Accelerating Growth". Barcelona. 2014-02-24
3P Biopharmaceuticals S.L.. (12/20/13). "Press Release: Dámaso Molero, a New Member of the Board of Directors of Asebio". 2013-12-20
Merck KGaA. (12/18/13). "Press Release: Merck Enters into License Agreement with the Spanish National Cancer Research Centre (CNIO)". Darmstadt. 2013-12-18
Recordati Industria Chimica e Farmaceutica S.p.A.. (10/21/13). "Press Release: Recordati Finalizes Its Acquisition of Laboratorios Casen Fleet in Spain". Milan. 2013-10-21
Recordati Industria Chimica e Farmaceutica S.p.A.. (9/9/13). "Press Release: Recordati Acquires Spanish Pharmaceutical Company Laboratorios Casen Fleet". Milan. 2013-09-09
Almirall S.A.. (7/29/13). "Press Release: Almirall’s H1 – Executing on Growth Platforms, Financial Delivery on Track". Barcelona. 2013-07-29
Metabolon, Inc.. (7/9/13). "Press Release: IMDEA Food and Metabolon, Inc. Announce Strategic Collaboration to Advance Nutrition-based Personalized Medicine". Research Triangle Park, NC. 2013-07-09
Almirall S.A.. (5/7/13). "Press Release: Almirall Begins the Transformation. Q1 Results on Track to Achieve Yearly Guidance". Barcelona. 2013-05-07
Sygnis Pharma AG. (4/30/13). "Press Release: Sygnis Reports Financial Results for Fiscal Year 2012". Heidelberg. 2013-04-30
Myriad Genetics, Inc.. (3/26/13). "Press Release: Myriad and PharmaMar Announce First Commercial Partnership with Myriad’s New HRD Test". Salt Lake City, UT. 2013-03-26
Sygnis Pharma AG. (3/25/13). "Press Release: Sygnis Announces Management Board Changes (Ad hoc-Release)". Heidelberg & Madrid. 2013-03-25
Zeltia S.A.. (2/28/13). "Press Release: Zeltia Posts Net Attributable Profit of €6.6 Million (+39%)". Madrid. 2013-02-28
Zeltia S.A.. (2/27/13). "Press Release: Zeltia Announces that Subsidiary Sylentis Has Commenced Phase II Clinical Trials with Compound SYL1001 for Treating Eye Discomfort Associated with Dry Eye Syndrome". Madrid. 2013-02-27
Ability Pharmaceuticals S.L.. (2/5/13). "Press Release: Ability Pharmaceuticals Awarded a 1.2 Million Euros Grant to Develop Its Lipid Analog ABTL0812 for Lung and Pancreatic Cancer. The Grant Will Fund the First-in-Man Phase Ib Clinical Trial". Bellater 2013-02-05
Scienion AG. (2/4/13). "Press Release: Scienion’s sciFlexarrayer Used for Cantilever Biosensor Production of Madrid-based Bionanomechanics Lab in Collaboration with Mecwins". Dortmund & Berlin. 2013-02-04
Zeltia S.A.. (1/22/13). "Press Release: Genomica AB Starts Its Commercial Activity". Madrid. 2013-01-22
Sygnis Pharma AG. (12/20/12). "Press Release: Sygnis Announces the Adaptation of Its Organisation to the New Business Activity". Heidelberg. 2012-12-20
Sygnis Pharma AG. (12/6/12). "Press Release: Sygnis Announces Completion of the X-Pol Biotech Acquisition. Registration of the Transaction and the Previous Capital Reduction (Ratio 8:1) in the Commercial Register". Heidelberg. 2012-12-06
Sygnis Pharma AG. (11/14/12). "Press Release: Sygnis Announces Six Months Results of Fiscal Year 2012". Heidelberg. 2012-11-14
Zeltia S.A.. (11/7/12). "Press Release: PharmaMar Germany Commences Commercial Activity". Madrid. 2012-11-07
Scienion AG. (11/5/12). "Press Release: Joint Technologies – Scienion and Genomica Expand Collaboration to Provide Innovative Printing Technology for Multiple Applications. Companies Jointly Present at Medica, November 14–17, 2012, in Düsseldorf". Berlin 2012-11-05
Zeltia S.A.. (10/25/12). "Press Release: Zeltia Group Operating Revenues up 7%". Madrid. 2012-10-25
Sygnis Pharma AG. (10/18/12). "Press Release: Annual General Meeting of Sygnis Pharma AG Approves Combination of Businesses with X-Pol Biotech. Comprehensive Strategic Realignment Agreed – Election of New Supervisory Board". Heidelberg. 2012-10-18
Ability Pharmaceuticals S.L.. (9/21/12). "Press Release: AB-Therapeutics Closes 1 Million Euro Financing Round and Changes the Company Name to Ability Pharmaceuticals". Bellaterra (Barcelona). 2012-09-21
1 2  next pagenext page



Advertisement

Picture [iito] – Putting Information into Context 600x102px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px

» top